icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
7jcVWhpAtkGNzrsE